Search
forLearn
5 / 801 resultslearn PTD-DBM
learn HT-B
learn medium chain triglycerides
learn PTT-6®
Research
5 / 94 results
research Tissue Harvesting | HuBMAP | JHU-TMC v1
research Sticking It to Alopecia
Triamcinolone acetonide injections help regrow hair in alopecia areata patients.
research Identification and characterization of genes for skin and hair disorders
New gene variants were found for rare skin and hair disorders, improving understanding and treatment.
research Histopathological Characteristics may not be Useful in the Differential Diagnosis Between Basal Cell Carcinoma and Benign Tumors of Cutaneous Appandages Originating from Hair Follicle
Looking at tissue characteristics isn't reliable for telling apart basal cell carcinoma from certain benign skin tumors.
research Thymic Mesenchymal Cells Have a Distinct Transcriptomic Profile
Thymic mesenchymal cells have unique gene expression that supports their specific functions in the thymus.
Community Join
5 / 1000+ resultscommunity How finasteride lowers brain's happiness steroid allopregnanolone and causes depression: systemic dihydroprogesterone crosses blood brain barrier, you don't even need finasteride and brain 5ar for that
Finasteride may lower allopregnanolone levels, potentially affecting mood, but many users report improved mental health due to reduced hair loss. Experiences with finasteride and dutasteride vary, with some experiencing side effects and others finding them beneficial for hair retention and overall happiness.
community Ordered PTD-DBM from tailor made
The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community Why TDM-105795 is not much talked about like GT20029 and HMI 115 despite having far better Trial results?
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.